Rare and Orphan Disease Research and What It Means for Oncology Drug Development

Scientist Looking At Orphan Disease Research
By Mireille Cantarini, BSc, MB ChB, MRCP, FFPM, Vice President, Therapeutic Area Operational Strategy Lead, Hematology and Oncology,

  Extensive research and drug development lies at the core of modern medicine. However, when it comes to an orphan indication or rare disease research and drug development, big pharmaceutical organizations are reluctant to invest because of perceived limited commercial viability. Our latest blog explores why it matters to invest in orphan disease research and development and what it means for clinical researchers in the oncology space.

Read More